Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model.
Diabetic patients have an increased risk of prosthesis failure requiring revision surgery. Furthermore, skeletal defects are observed in conjunction with type 1 diabetes. Using a titanium particle-induced calvarial osteolysis model in diabetic mice, we investigated the effect of diabetes on the osteolytic process and the role of naringin in its prevention. Three groups each of nondiabetic or diabetic mice were treated with vehicle only, with particles only, or with particles then naringin for 10 days. Alteration of bone indices near the midline suture were then analyzed by microcomputed tomography scanning and histology. Serum levels of osteocalcin (OCN) and cross-linked N-telopeptide of type I collagen (NTx) were measured by enzyme-linked immunosorbent assay. The decreases in new bone formation (p < 0.05), calvaria thickness (p < 0.05), bone volume (p < 0.05), midline suture area (p < 0.05), and OCN concentration (p < 0.05) found in diabetic mice were normalized with naringin treatment. Diabetic state promoted particle-induced osteolysis. Naringin, an osteoanabolic agent, improved bone indices apparently by stimulating bone formation. Therefore, naringin may be beneficial in preventing and treating debris-mediated periprosthetic osteolysis after total joint replacement, especially in diabetics.
Zhou
Xiaoxiao
X
Department of Orthopaedics, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, People's Republic of China.
Zhang
Peng
P
Zhang
Chao
C
Zhu
Zhen'an
Z
D000818:Animals; D018786:Bone Substitutes / Q000737:chemistry; D024042:Collagen Type I / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D004365:Drugs, Chinese Herbal; D044950:Flavanones / Q000494:pharmacology*; D017102:Fracture Healing / Q000187:drug effects* / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D010014:Osteolysis / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D010455:Peptides / Q000097:blood; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology; D029621:Polypodiaceae / Q000737:chemistry; D012886:Skull / Q000187:drug effects* / Q000473:pathology; D014025:Titanium / Q000737:chemistry; D014057:Tomography, X-Ray Computed
D018786:Bone Substitutes; D024042:Collagen Type I; D004365:Drugs, Chinese Herbal; D044950:Flavanones; D010455:Peptides; D010936:Plant Extracts; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D014025:Titanium; C005274:naringin